 |
On the basis of
the HERS results, the investigators concluded that a woman with CHD who is already on
hormone-replacement therapy should not discontinue therapy, because hormone treatment
reduced CHD risk at later time points during the study. However, with the lack of overall
CHD benefit combined with a trend toward increased CHD risk, the authors did not recommend
initiating hormone-replacement therapy as secondary prevention in a woman not currently on
therapy. Reference:
Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart
and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of
estrogen plus progestin for secondary prevention of coronary heart disease in
postmenopausal women. JAMA 1998;280:605-613. |
